setron 1 mg
padagis israel agencies ltd, israel - granisetron as hydrochloride - tablets - granisetron as hydrochloride 1 mg - granisetron - granisetron - prevention of nausea and vomiting induced by cytostatic therapy.
palonosetron stada 250 mikrogramov raztopina za injiciranje
stada arzneimittel ag - palonosetron - raztopina za injiciranje - palonosetron 250 µg / 1 viala - palonosetron
palonosetron fresenius kabi 250 mikrogramov raztopina za injiciranje
fresenius kabi deutschland gmbh - palonosetron - raztopina za injiciranje - palonosetron 250 µg / 1 viala - palonosetron
palonosetron sandoz 250 mikrogramov raztopina za injiciranje
sandoz d.d. - palonosetron - raztopina za injiciranje - palonosetron 250 µg / 1 viala - palonosetron
ondansetron ebewe 4 mg filmsko obložene tablete
ebewe pharma - ondansetron - filmsko obložena tableta - ondansetron 4 mg / 1 tableta - ondansetron
ondansetron ebewe 8 mg filmsko obložene tablete
ebewe pharma - ondansetron - filmsko obložena tableta - ondansetron 8 mg / 1 tableta - ondansetron
ondansetron teva 4 mg filmomh. tabl.
teva pharma belgium sa-nv - ondansetronhydrochloride 5 mg - eq. ondansetron 4 mg - filmomhulde tablet - 4 mg - ondansetronhydrochloride 5 mg - ondansetron
ondansetron teva 8 mg filmomh. tabl.
teva pharma belgium sa-nv - ondansetronhydrochloride 10 mg - eq. ondansetron 8 mg - filmomhulde tablet - 8 mg - ondansetronhydrochloride 10 mg - ondansetron
palonosetron injection, solution
dr.reddy's laboratories limited - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - palonosetron 0.05 mg in 1 ml - palonosetron hydrochloride injection is indicated in adults for prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). - acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (hec). - postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride is recommended even where the incidence of postoperative nausea and/or vomiting is low. palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: - acute nausea and vomiting associated with initial and repea
palonosetron hydrochloride injection, solution
sandoz inc - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - palonosetron 0.25 mg in 5 ml - palonosetron injection is indicated in adults for prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). - acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (hec). - postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, palonosetron is recommended even where the incidence of postoperative nausea and/or vomiting is low. palonosetron hcl injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: • acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemoth